| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $3,086 | 3 | 100 |
| Dooley Mary Beth | Head of Finance | 0 | $0 | 3 | $3,086 | $-3,086 |
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Synlogic, Inc. have bought $0 and sold $3,086 worth of Synlogic, Inc. stock.
On average, over the past 5 years, insiders at Synlogic, Inc. have bought $10,640 and sold $12,108 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 9,500 shares for transaction amount of $10,640 was made by JENSEN MICHAEL VANGSTED (Chief Financial Officer) on 2022‑05‑24.
| 2025-04-02 | Sale | Dooley Mary Beth | See Remarks below | 144 0.0012% | $1.20 | $173 | -2.92% | |
| 2025-02-03 | Sale | Dooley Mary Beth | See Remarks below | 2,107 0.0172% | $1.33 | $2,802 | -7.58% | |
| 2024-10-29 | Sale | Dooley Mary Beth | Head of Finance | 79 0.0006% | $1.40 | $111 | -9.59% | |
| 2024-04-02 | Sale | Awad Antoine | Chief Operating Officer | 372 0.0031% | $1.73 | $644 | -17.05% | |
| 2024-04-02 | Sale | Dooley Mary Beth | Head of Finance | 188 0.0016% | $1.73 | $325 | -17.05% | |
| 2023-04-03 | Sale | Brennan Aoife | See Remarks | 19,042 0.0274% | $0.58 | $10,964 | -52.18% | |
| 2023-04-03 | Sale | Awad Antoine | Chief Operating Officer | 6,438 0.0093% | $0.58 | $3,707 | -52.18% | |
| 2023-04-03 | Sale | JENSEN MICHAEL VANGSTED | Chief Financial Officer | 2,553 0.0037% | $0.58 | $1,470 | -52.18% | |
| 2022-05-24 | JENSEN MICHAEL VANGSTED | Chief Financial Officer | 9,500 0.0132% | $1.12 | $10,640 | -20.37% | ||
| 2022-04-04 | Sale | Brennan Aoife | See Remarks | 8,894 0.0129% | $2.45 | $21,754 | -57.72% | |
| 2022-04-04 | Sale | Awad Antoine | Chief Operating Officer | 2,650 0.0039% | $2.45 | $6,482 | -57.72% | |
| 2019-12-13 | Shea Richard P | director | 7,500 0.0252% | $2.74 | $20,550 | -7.99% | ||
| 2019-02-13 | Sale | Miller Paul Francis | Chief Scientific Officer | 5,849 0.022% | $9.75 | $57,028 | -53.62% | |
| 2019-02-12 | Sale | Miller Paul Francis | Chief Scientific Officer | 3,151 0.0127% | $9.75 | $30,722 | -50.06% | |
| 2018-10-18 | Sale | Miller Paul Francis | Chief Scientific Officer | 3,000 0.0132% | $9.77 | $29,296 | -16.09% | |
| 2018-09-18 | Sale | Miller Paul Francis | Chief Scientific Officer | 3,000 0.0119% | $13.05 | $39,163 | -38.59% | |
| 2018-09-05 | Sale | Miller Paul Francis | Chief Scientific Officer | 3,000 0.0117% | $12.55 | $37,635 | -36.75% | |
| 2018-08-30 | Sale | Miller Paul Francis | Chief Scientific Officer | 1,342 0.0052% | $9.76 | $13,092 | -19.08% | |
| 2018-08-29 | Sale | Miller Paul Francis | Chief Scientific Officer | 1,658 0.0067% | $9.77 | $16,198 | -15.54% | |
| 2018-07-18 | Sale | Miller Paul Francis | Chief Scientific Officer | 3,000 0.0118% | $11.01 | $33,022 | -25.32% |
| Dooley Mary Beth | See Remarks below | 12901 0.1103% | $19,480.51 | 0 | 4 | |
| POWELL MICHAEL | 2974811 25.4342% | $4.49M | 1 | 0 | ||
| Sofinnova Venture Partners VIII, L.P. | 10 percent owner | 2974811 25.4342% | $4.49M | 1 | 0 | |
| BARRIS PETER J | 10 percent owner | 2971517 25.406% | $4.49M | 1 | 0 | |
| BARRETT M JAMES | 10 percent owner | 2971517 25.406% | $4.49M | 1 | 0 | |
| MOTT DAVID M | 10 percent owner | 2971517 25.406% | $4.49M | 1 | 0 | |
| KERINS PATRICK J | 10 percent owner | 2971517 25.406% | $4.49M | 1 | 0 | |
| SANDELL SCOTT D | 10 percent owner | 2971517 25.406% | $4.49M | 1 | 0 | |
| KOLLURI KRISHNA KITTU | 10 percent owner | 2971517 25.406% | $4.49M | 1 | 0 | |
| BASKETT FOREST | 10 percent owner | 2971517 25.406% | $4.49M | 1 | 0 | |
| Weller Harry R | 10 percent owner | 2971517 25.406% | $4.49M | 1 | 0 | |
| Viswanathan Ravi | 10 percent owner | 2971517 25.406% | $4.49M | 1 | 0 | |
| New Enterprise Associates 14, L.P. | 10 percent owner | 2971517 25.406% | $4.49M | 1 | 0 | |
| Sonsini Peter W. | 10 percent owner | 2971517 25.406% | $4.49M | 1 | 0 | |
| Florence Anthony A. Jr. | 10 percent owner | 2971517 25.406% | $4.49M | 1 | 0 | |
| PFIZER INC | 10 percent owner | 2253509 19.2672% | $3.4M | 1 | 0 | |
| Brennan Aoife | See Remarks | 256301 2.1913% | $387,014.51 | 0 | 2 | |
| Miller Paul Francis | Chief Scientific Officer | 48135 0.4115% | $72,683.85 | 0 | 10 | |
| JENSEN MICHAEL VANGSTED | Chief Financial Officer | 46947 0.4014% | $70,889.97 | 1 | 1 | <0.0001% |
| Awad Antoine | Chief Operating Officer | 33859 0.2895% | $51,127.09 | 0 | 3 | |
| Irvin Jon | Vice President, Finance | 7625 0.0652% | $11,513.75 | 0 | 5 | |
| Shea Richard P | director | 7500 0.0641% | $11,325.00 | 1 | 0 | <0.0001% |
$53,490,060 | 55 | 19.35% | $20.45M | |
$395,438 | 43 | -21.25% | $16.52M | |
$1,443,732 | 36 | 10.14% | $20.49M | |
$95,303,339 | 30 | -13.78% | $14.72M | |
$1,995,470 | 22 | 14.01% | $21.91M | |
$226,127 | 22 | -27.62% | $15.87M | |
$555,628 | 21 | 43.52% | $16.96M | |
$114,405,653 | 19 | -5.40% | $15M | |
$112,810,270 | 18 | -1.20% | $18.1M | |
$122,973 | 15 | -26.96% | $18.48M | |
$25,487,383 | 15 | -4.37% | $21.6M | |
$1,199,157 | 14 | 7.52% | $20.12M | |
$39,336,371 | 14 | -17.87% | $17.99M | |
$389,864 | 11 | 12.52% | $15.42M | |
$20,715,938 | 10 | -42.51% | $21M | |
$11,777,042 | 10 | -11.94% | $16.65M | |
$2,060,158 | 5 | -21.35% | $16.99M | |
$82,917 | 4 | -11.54% | $16.95M | |
Synlogic, Inc. (SYBX) | $31,190 | 2 | -14.18% | $17.66M |
| Increased Positions | 4 | +23.53% | 18,822 | +0.28% |
| Decreased Positions | 3 | -17.65% | 2,431 | -0.04% |
| New Positions | <1 | New | 17,520 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 18 | +5.88% | 7M | +0.24% |
| Cable Car Capital, Lp | $3,975.00 | 27.6% | 3.31M | 0 | 0% | 2024-12-31 |
| Nea Management Company, Llc | $3,507.00 | 24.36% | 2.92M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $220.00 | 1.53% | 183,002 | 0 | 0% | 2024-12-31 |
| Fmr Llc | $200.00 | 1.39% | 166,724 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $82.00 | 0.57% | 68,445 | +4,211 | +6.56% | 2024-12-31 |
| Fiduciary Trust Co | $27.00 | 0.19% | 22,352 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $27.00 | 0.19% | 22,310 | -49,618 | -68.98% | 2024-12-31 |
| Ikarian Capital, Llc | $25.00 | 0.17% | 20,422 | -26 | -0.13% | 2024-12-31 |
| Blackrock, Inc. | $24.00 | 0.17% | 19,757 | 0 | 0% | 2025-03-31 |
| Abg Innovation Capital Partners Iii Gp Ltd | $16.00 | 0.11% | 13,727 | 0 | 0% | 2024-12-31 |